Cessation or dose reduction of Capecitabine due to Complications in Patients with Colon Cancer

the cessation of capecitabine a ects the recurrence rate, but dose reduction does not.  is study presents a clinical guideline that chemotherapy using capecitabine should be continued even when the dose must be reduced because of complications. As indicated above, this study will become more meaningful if the dependences of the prognostic factors related to oncologic outcomes on dose reduction, dose cessation and complications can be determined by increasing the number of candidates and by lengthening follow-up period. Also, studies on the manifestation of the hydropyrimidine dehydrogenase gene, which is supposed to be related to complications of capecitabine [2] are necessary.